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or the most part unknown. Of >100 countries that are not
apacitated to report TB resistance surveillance to WHO,
he majority reside in Africa. Global estimates are there-
ore extrapolated from different sources. The South African
DR/XDR TB burden is similarly estimated and for the most
art incomplete.
Discussion: An MDR TB survey of 2001 (MRC) estimated
he burden of MDR TB at levels between 1—3% with isolated
otspots. It was not designed to estimate XDR TB and was
classic ‘‘point prevalence’’ study that sampled from lim-
ted sites. KZN has been the only South African province
ith an expanded portfolio of routine susceptibility test-
ng for second-line drugs for all clinical isolates. ‘‘XDR’’ TB
as been documented since the late 1980’s and described in
reatment cohorts admitted for care. These results will be
resented. The TFO however recorded the highest cluster of
ndividual cases ever reported and exposed the limitations of
he current surveillance strategy that depended on periodic
ross-sectional surveys. As a result the MRC has embarked
n a rapid surveillance project identifying regions in the
rovince where XDR TB has been identiﬁed and targeting
hese settings for an in-patient and out-patient surveillance
roject.
Conclusions: The recommendation for a continuous,
xpanded, country-wide surveillance system is self-evident
f only to accurately inform the currently straining program-
atic management of drug-resistant TB and to provide the
arly warning signals of programmatic failure.
oi:10.1016/j.ijid.2008.05.126
4.002
DR-TB and XDR-TB in Asia
.E. Tupasi
Tropical Disease Foundation, Makati, Metro Manila,
hilippines
t is estimated that there were 149,615 (95% CLs,
14,780—217,921) incident MDR-TB cases in South East Asia
n 2006, 74% were in India while there were 152,694 (95%
Ls, 119,886—188,014) incident MDR-TB cases in the the
estern Paciﬁc region in 2006, with almost 85% of these
ases estimated to be in China. The proportion of XDR-TB
mong MDR-TB was highest in Japan, 30.9% followed by
4.6% in Hong Kong, SAR, 3.4% Philippines, 1.8% Korea, 1%
angladesh, and one case each in Vietnam, India, China and
epal. Population-based studies still have to be undertaken
o know the real magnitude of XDR-TB.
Extensively drug-resistant TB (XDR-TB) was ﬁrst
escribed in 2006 in 40 0f 49 countries studied with
% of MDR-TB isolates in the USA, 19% in Latvia and 15% in
orea among chronic cases. An outbreak of XDR-TB among
4 patients with a high prevalence of HIV in South Africa
eported in 2006 was characterized by high early mortality
f 98% and nosocomial transmission as well as transmision
n the community. This outbreak demonstrated that XDR-TB
s a threat to both TB and HIV control and emphasized
he need for infection control measures in health facility
ettings.
XDR, deﬁned as MDR-TB plus simultaneous resistance
o a ﬂuoroquinolone and an injectable second line anti-
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B drug, showed a cure rate that was signiﬁcantly low
nd a failure rate that was high compared to other MDR-
B patients in Latvia. To respond to this crisis, the WHO
lobal Response plan 2007—2008 emphasized the need to
trengthen basic DOTS and HIV programs, to scale up the pro-
rammatic management of MDR-TB, strengthen laboratory
ervices to support M(X)DR-TB diagnosis, expand M(X)DR-TB
urveillance to study trends and link with HIV, foster sound
nfection control, promote research on the development
f new diagnostics, drugs, and vaccines. Much like MDR-
B which is the consequence of poor DOTS, XDR-TB is the
onsequence of poor MDR-TB management.
oi:10.1016/j.ijid.2008.05.127
4.003
apid Diagnosis of MDR-TB in Low-resource Settings
.A.J. Moore
Wellcome Centre for Clinical Tropical Medicine Imperial
ollege London, London, United Kingdom
ccording to the inverse-care law, the highest standard of
are is least available to those most in need. Diagnosis of
rug-resistant TB has long been a clear example of this
henomenon. In recent years a number of candidate diag-
ostic tests have been developed in both the academic and
ommercial sectors which present potential opportunities
o aggressively address this inequity. This talk will discuss
ome of the currently available tools that are suitable for
esource-limited settings, their relative merits and draw-
acks, and a number of implementation challenges common
o all, drawing on experience from Peru.
oi:10.1016/j.ijid.2008.05.128
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he Epidemiology of MDR-TB in Peru
. Gotuzzo
Instituto de Medicina Tropical ‘Alexander Von Humboldt’,
ima, Peru
B in Peru has been known since the pre-hispanic period in
ommies.
Peru and Haiti has had the highest rate of prevalence in
merica (>160× 105 per habitant), where more than 65% of
ases of pulmonary TB has sputum positive.
Recently, the WHO recognized the Peruvian DOT as one
f the best worldwide programs to have reach the two goals
f the DOT (Diagnosis in more than 90% cases and cure rate
ore than 90%) decreasing the incidence in 5-6% per year in
he last 10 years.
However, in the shanty towns of Lima, the rate of MDR-
B has being increasing in an important way, spreading to
rban parts of the big cities. Leaving in the North of Lima
as been noted as a risk factor, where the primary rate of
DR TB is 6%, while in the South of Lima is just 2%. The most
now risk factors are having an intra-domiciliary TB contact
nd a treatment failure in the second of month of the ﬁrst
ine therapy; others include Diabetes Mellitus, AIDS/HIV and
ealth care workers. Also, 10-15% of MDR TB cases are XDR.
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This form of resistance has been detected in Peru since 1996.
We have an excellent DOT with very good outcomes, how-
ever, the paradox of having a sensible TB and a growth of
MDR TB is no easy to explain.
We could try to explain the reasons due to a low preva-
lence of Beijing strain (<10%) and administrative delay in
starting speciﬁc treatment of 12—15 months detected in the
period of 1995 to 2003. This administrative delay happened
because after a treatment failure to ﬁrst and second line
therapy, an overall of 12 months; at this moment, cultures
and diagnosis for INH/Rifampin resistance were taken. The
results took about 3 months, and it was then when we could
start a speciﬁc treatment.
During all this time, is estimated that a TB patient
could infect between 2 to 25 people. This situation could
be the cause of infection in the homes, health centers
care, patients in the ER with predisposition like AIDS/HIV
and Diabetes, and Health Care Personnel that took care of
this patients without an adequate protection. Newcomer’s
molecular studies could help to ﬁnd the answers to this spe-
cial situation.
doi:10.1016/j.ijid.2008.05.129
Controlling Japanese Encephalitis: Advances in Detection
and Prevention (invited)
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Measuring Japanese Encephalitis Disease Burden:
Challenges in Surveillance and Diagnostics
M. Fischer1,∗, S. Hills 2, E. Staples1, B. Johnson1, M. Yaich2,
T. Solomon3
1 CDC, Fort Collins, CO, USA
2 PATH, Seattle, WA, USA
3 University of Liverpool, Liverpool, United Kingdom
Japanese encephalitis (JE) is a signiﬁcant but solvable pub-
lic health problem. Safe, effective, and affordable vaccines
are available to prevent this devastating disease. However,
the introduction or expansion of JE immunization programs
is often delayed because disease burden is unknown or
underestimated. In several countries where JE virus trans-
mission has been proven and sporadic cases have been
recognized, JE surveillance does not exist. In other coun-
tries, the quality and accuracy of existing surveillance data
are uncertain. Although WHO has published JE surveillance
standards, these guidelines have yet to be implemented in
most countries. Therefore, the numbers and characteristics
of JE cases cannot be easily compared between countries or
over time. In addition, long-term sequelae associated with
JE are often not measured, resulting in an underestimate of
the full economic and social impact of the disease. Most
JE cases are diagnosed based on clinical syndrome (i.e.,
encephalitis) without laboratory conﬁrmation. This practice
can perpetuate established biases in the epidemiology of JE
because cases are only reported from known endemic areas
during predeﬁned transmission seasons. As a result, JE may
be underreported from areas that lack well-deﬁned seasonal
peaks in encephalitis cases, or among patients with unique
clinical presentations (i.e., acute ﬂaccid paralysis) or demo-
graphics (i.e., adults). In addition, encephalitis cases due
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o other etiologies are erroneously attributed to JE virus
nfection and sometimes misclassiﬁed as vaccine failures
r vaccine-associated adverse events. Although many lab-
ratories perform JE diagnostic testing, several steps are
eeded to ensure the accuracy, reliability, and compara-
ility of the results. Laboratories supporting surveillance
fforts should use validated diagnostic assays and standard-
zed testing protocols with strong quality assurance and
uality control programs. Improved surveillance with accu-
ate laboratory-based diagnostics is an essential step for
etter understanding the epidemiology and true burden of
E, and for directing and evaluating effective immunization
trategies.
oi:10.1016/j.ijid.2008.05.130
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eographical Extent and Disability from the Disease
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usilarini 1, V. Moniaga2,3, A. Sasmito2,3, D. Yuwono1, G.
ahyuhono1, M. Sembiring Maha1, A. Suwandono1
National Institute of Health Research and Development,
akarta, Indonesia
Program for Appropriate Technology in Health, Seattle,
SA
Program for Appropriate Technology in Health, Jakarta,
ndonesia
ackground: A two-year prospective study was conducted
rom January 2005 to December 2006 to estimate the mag-
itude of Japanese encephalitis (JE) disease burden in
ndonesia. All children 15 years of age and under presenting
ith acute encephalitis syndrome (AES) to selected hospital
nd health center sites were identiﬁed and laboratory test-
ng was conducted to conﬁrm the proportion of cases due to
E virus infection. Epidemiological data were collected to
mprove understanding of JE disease in Indonesia.
Methods: Six provinces with different assumed risks for
E virus transmission were included. At ﬁfteen hospital and
ealth center sites, paired sera, cerebrospinal ﬂuid samples,
nd at some sites ﬁlter paper specimens, were taken from
atients whomet theWHO criteria for AES. They were tested
or antibody to JE and dengue viruses using immunoglobulin
antibody capture ELISA at the National Institute of Health
esearch and Development in Jakarta.
Results: 1496 AES patients (1401 from hospitals, 95 from
ealth centers) were recorded. 74.9% (n = 1120) were <5
ears old, and 57.6% (n = 862) were male. 82 patients (5.5%)
ad IgM antibody to JE virus: of these, 70.7 % (n = 58) were
ged <5 years, and 56.1% (n = 46) were males. The average
ength of hospitalization of JE positive patients was sig-
iﬁcantly longer than those who tested JE negative (12.7
ays and 8.8 days, respectively; p = 0.03); they were also
ore likely to suffer from sequelae than those without JE
RR = 3.12; p < 0.001). Having pig rearing nearby (less than
km from the house) was the main risk factor associated
ith acute JE infection (p = 0.004). However, about half of
he JE patients did not live close to a pig population, sug-
esting that other amplifying hosts such as water birds are
lso involved in JE virus transmission in Indonesia.
